Catalyst
Slingshot members are tracking this event:
Acadia's (ACAD) Pimavanserin in Alzheimer’s disease psychosis PDUFA date set for April 3, 2021, after FDA identified deficiencies that preclude discussion of labeling
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ACAD | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 05, 2021
Occurred Source:
https://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-receives-complete-response-letter-us-fda
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pimavanserin, Alzheimer's Disease, Alzheimer's Psychosis
